Purpose or Objective: Ductal carcinoma in situ (DCIS) represents around 20% of breast cancers (BC). Standard treatment after breast conserving surgery is still adjuvant radiotherapy (RT). Several randomized trials and metaanalysis showed a 50% risk reduction in LR after adjuvant RT. The aim of our analysis was to evaluate the LR rate and possibly to identify a risk groups stratification for DCIS treatment optimization.
Material and Methods:
We analyzed 457 patients that underwent BCS and adjuvant RT between 1990 and 2012. Median dose to the whole breast was 50 Gy in 25 fractions; patients with positive/close final surgical margins received a tumor bed boost. We stratified patients in low risk group using well known risk factor for LR (n= 203; age ≥50 years, surgical margins ≥10 mm, nuclear grade 1 -2, pT ≤25 mm), and intermediate-high risk group (n= 254; age <50 years, surgical margins <10 mm, nuclear grade 3 or pT >25 mm). We performed also a patient startification according to Van Nuys Prognostic Index. Estrogen and progesterone receptors status, nuclear grade, and Ki-67 proliferative index were available for most patients.
Results:
The mean age was 57 years (range 33-80). Hormonal status was positive in 92% of patients, 83 cases (18.2%) received adjuvant endocrine therapy. All patients received postoperative RT, 198 cases (43%) received also a RT boost on tumor bed. At a median follow up time of 12 years (range 3-23), we observed 26 LR (5.6%). Following risk groups stratification, we observed seven LR (3.4%) in low risk group and nineteen LR (7.4%) in intermediate-high risk group (p<0.001).
Conclusion:
Our experience evidenced a significant difference in LR incidence after adjuvant RT based on our risk factors stratification. This confirms the wide heterogeneity of DCIS. Identification of clear subgroups of patients following risk factors is still lacking. Waiting for results from ongoing clinical phase 3 trials and genomic studies, postoperative RT still remains a mainstay in adjuvant treatment for DCIS.
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Material and Methods:
For fourteen patients with right-sided breast cancer, forward IMRT plans were calculated on freebreathing (FB) and vmDIBH CT-scans, for local-as well as locoregional breast treatment, with and without internal mammary lymph nodes (IMN). We compared dose volume parameters to estimate the reduction in the risk of radiation pneumonitis, the influence on pulmonary lung function tests and the risk of secondary lung cancer with the use of vmDIBH.
Results: For local breast treatment, no relevant reduction in mean lung dose (MLD) was found. For locoregional breast treatment without IMN, the average MLD reduced from 6.5 to 5.4 Gy (p<0.005) for the total lung and from 11.2 to 9.7 Gy (p<0.005) for the ipsilateral lung. For locoregional breast treatment with IMN, the average MLD reduced from 10.8 to 9.1 Gy (p<0.005) for the total lung and from 18.7 to 16.2 Gy (p<0.005) for the ipsilateral lung. We also found a reduction in mean heart dose between 0.6 and 2.6 Gy in four patients; with a mean of 0.4 Gy for all 14 patients together (p= 0.07). We estimate that 1 out of 100 patients will not develop radiation pneumonitis when breath-hold is applied during locoregional right-sided breast cancer treatment. For eversmoking women, the risk of secondary lung cancer might also be reduced by vmDIBH.
Conclusion:
Breathing adapted radiation therapy in patients with left-sided breast cancer is becoming widely introduced. As a result of the slight reduction in lung dose found for
